Expression data from tumor lungs after continuous vs. pulsatile selumetinib treatment in KRASG12C GEMM

Default Boolean Operator: Terms in a search string will be connected by the AND operator, EXAMPLE: searching genomic melanoma will produce the same results as genomic AND melanoma .
AND, OR, NOT: Combine terms in a search with the boolean operators AND (to add specificity), OR (to broaden), or NOT (to eliminate a term). Operators must be capitalized (all other search terms are not case-sensitive).
Wild Card: Add wild card symbols * (open-ended) and ? (single character) to truncate terms. EXAMPLE: searching gen* shows results for 'gene', 'genetic', 'genomic, etc. Searching gene? returns results for 'gene' or 'genes' but not for 'genome'.
Phrase Searching: Enclose search in quotation marks "keyword or search term" to search for an exact phrase. EXAMPLE: "transcription factors" returns results for records where transcription is immediately followed by the word factors .
Diacritics: Words containing diacritics translate those characters to non-diacritic form. EXAMPLE: massague returns results for Massague&#769 .
Filter by: Located on the homepage (left panel), use filters to search for records or narrow the search. From search results page, filters can be removed by clicking on the term at the top of the page.

UID: 11018

Author(s): Choi, Hyejin*, Deng, Jiehui, Li, Shuai, Wong, Kwon-Kin, Wolchok, Jedd D.*, Merghoub, Taha* * MSK affiliated

Description: Summary from GEO:

"KRAS is one of the driver oncogenes in non-small cell lung cancer (NSCLC), but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK to circumvent KRAS activation. Here, we show that pulsatile, rather than continuous, treatment with MEK inhibitors (MEKis) maintains T cell activation and better control tumor growth and survival.
We used microarrays to examine the MAPK signaling pathway suppression from tumor lungs of KRASG12C GEMM after continuous vs. pulsatile treatment of selumetinib."

Overall design from GEO:

"Tumor was induced by intranasal administration of adenoviral-Cre to KRASLSL-G12C/+ GEMM mice. Once the tumor size reached approximately 500 mm3 (at about 12 weeks after adenoviral inoculation), KRASG12C GEMM mice were treated with selumetinib continuously (daily for 3 weeks, 25mg/kg, BID) or pulsatilely (1 cycle: 1 week ON + 1 week OFF, total 3 cycles, 25mg/kg, BID) with their matched control (vehicles), since the treatments were not done at the same time. The mice were sacrificed after selumetinib treatment is completed."

Subject of Study

Subject(s)

OncoTree Cancer Type(s)

Non-Small Cell Lung Cancer

Do you have or know of a dataset that should be added to the catalog? Let us know!